

3, 5-13, 32-35

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. cancelled
2. cancelled
3. (original) A nucleic acid construct comprising a SIV-1 gag gene having the coding sequence of the gag gene set forth in Figure 3. → 6A6
4. cancelled
5. (currently amended) A vector comprising the nucleic acid construct of Claim 1, 2, 3 or 4.
6. (currently amended) A transformed host cell comprising the nucleic acid construct of Claim 1, 2, 3 or 4.
7. (original) A transformed host cell of Claim 6 wherein said cell is a eukaryote.
8. (original) The host cell of Claim 7 wherein said cell is a human cell.
9. (original) A transformed host cell of Claim 6 wherein said cell is a prokaryote.
10. (original) The host cell of Claim 9 wherein said cell is E. coli.

I. GAG N.A.

536/23.72

II. MATH USAGE I

424/198.1, 209.1

III. " " I

Page 3 of 5

IV. RWU N.A.

536/23.72

11. (currently amended) A pharmaceutical composition comprising the nucleic acid construct of Claim ~~1~~, ~~2~~, ~~3~~ or ~~4~~ and a pharmaceutically acceptable carrier.

12 12. (original) A method for inducing antibodies in a mammal comprising administering to a mammal a composition of claim 11, wherein said nucleic acid construct is present in an amount which is effective to induce said antibodies in said mammal.

13 13. (original) A method for inducing cytotoxic T lymphocytes in a mammal comprising administering to a mammal a composition of claim 11, wherein said nucleic acid construct is present in an amount which is effective to induce cytotoxic T lymphocytes in said mammal.

Claims 14-31 cancelled

32 32. (original) A nucleic acid construct comprising a SIV-1 *env* gene having the coding sequence of the *env* gene set forth in Figure 16. Seq 160 CTE

33. (original) A vector comprising the nucleic acid construct of claim 32.

34. (original) A transformed host cell comprising the nucleic acid construct of claim 32.

35. (original) A pharmaceutical composition comprising the nucleic acid construct of claim 32 and a pharmaceutically acceptable carrier.